<DOC>
	<DOC>NCT02281591</DOC>
	<brief_summary>Single centre, open-label, randomised study in four parallel groups of healthy volunteers</brief_summary>
	<brief_title>Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine</brief_title>
	<detailed_description>Single centre, open-label, randomised study in four parallel groups of healthy volunteers: Group 1 = 900 mg of eslicarbazepine acetate (ESL, BIA 2-093); Group 2 = 450 mg of S-licarbazepine plus 450 mg of R-licarbazepine; Group 3 = 450 mg of S-licarbazepine; Group 4 = 450 mg of Rlicarbazepine. In each group, the study consisted of a single-dose period (Phase A) followed by a repeateddose period of 7 days of duration in which the investigational product was administered once daily (Phase B). The repeated-dose phase started 96 h post single-dose.</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Inclusion Criteria Male or female subjects aged between 18 and 45 years, inclusive. Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive. Subjects who were healthy as determined by prestudy medical history, physical examination, vital signs, neurological examination, and 12lead ECG. Subjects who had clinical laboratory tests clinically acceptable at screening and admission. Subjects who had negative tests for HBsAg, antiHCV Ab and HIV1 and HIV2 Ab at screening. Subjects who were negative for drugs of abuse and alcohol at screening and admission. Subjects who were nonsmokers or who smoke &lt; 10 cigarettes or equivalent per day. Subjects who are able and willing to give written informed consent. (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence. (If female) She had a negative pregnancy test at screening and admission to Phase A. Subjects who did not conform to the above inclusion criteria, OR Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. Subjects who had a clinically relevant surgical history. Subjects who had a clinically relevant family history. Subjects who had a history of relevant atopy. Subjects who had a history of relevant drug hypersensitivity (especially carbamazepine or oxcarbazepine). Subjects who had a history of alcoholism or drug abuse. Subjects who consumed more than 14 units of alcohol a week. Subjects who had a significant infection or known inflammatory process on screening or admission.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>